Educational Notice
Peptidings provides information for educational and research purposes only. The peptides discussed on this page are subjects of ongoing scientific research. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Inflammation & Autoimmune Conditions
Inflammation is among the most cited targets for peptide research, and the mechanistic case for several compounds is genuinely well-developed. The translation from animal models to human autoimmune disease, however, is one of the most difficult problems in medicine—and most compounds in this space remain in preclinical or early clinical stages. Thymosin Alpha-1 is the notable exception: it holds regulatory approval in over 35 countries, making it one of the few peptides in this category with a substantial human evidence record.
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
It’s Complicated
Compounds with Research Relevant to Inflammation and Autoimmune Conditions
Each compound links to its full pillar article. The most useful sections for evaluating a specific application are the Claims vs. Evidence table and the Safety, Risks, and Limitations section. Evidence tiers reflect the strongest available data for a compound overall—not necessarily for this specific application.
GHK-Cu: What the Research Says about the Copper Peptide
Copper-binding tripeptide studied for wound healing, collagen synthesis, and skin remodeling. Evidence varies significantly by route of administration.
Read the research →
KPV (Lysine-Proline-Valine): Research Overview
C-terminal alpha-MSH tripeptide studied for anti-inflammatory effects in gut and wound models. Preclinical evidence only.
Read the research →
LL-37 (Cathelicidin): What the Research Shows
The only human cathelicidin, studied for antimicrobial activity and wound healing. Preclinical evidence only.
Read the research →
WADA
TB-500: What the Research Says about Thymosin Beta-4’s Synthetic Fragment
Synthetic Thymosin Beta-4 fragment studied for tissue repair and cell migration. Preclinical evidence only; WADA prohibited.
Read the research →
Thymalin: Thymic Peptide Bioregulator and Immunosenescence
Thymic polypeptide extract from Khavinson's bioregulator program. Approved and widely used in Russian medicine since the 1980s. Limited Western clinical data.
Read the research →
Thymosin Alpha-1 (Thymalfasin/Zadaxin): What the Research Shows
Endogenous thymic peptide approved in 35+ countries for hepatitis and immune modulation. Not FDA-approved in the US.
Read the research →
WADA
Thymosin Beta-4: What the Research Shows
Endogenous 43-amino acid actin-sequestering peptide studied for wound healing, cardiac repair (RGN-352 Phase II), and corneal regeneration (RGN-259). TB-500 is its synthetic fragment — distinct compounds.
Read the research →
VIP (Vasoactive Intestinal Peptide): What the Research Shows
Endogenous neuropeptide studied for anti-inflammatory, vasodilatory, and immune-modulatory effects. Phase II human data available.
Read the research →
Guides Relevant to This Condition
How to Reconstitute Lyophilized Peptides
Bacteriostatic water, reconstitution ratios, vial handling
Peptide Storage and Handling Best Practices
Temperature ranges, freeze-thaw cycles, reconstituted peptide shelf life
FDA Regulatory Explainer
Category 1, 2, and 3 compounds—what the classifications mean for research use
Research Cluster
These compounds are covered in depth in the Immune Health Peptides cluster hub.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.